You are currently on the new version of our website. Access the old version .
MDPIMDPI

5 Results Found

  • Interesting Images
  • Open Access
13 Citations
2,999 Views
7 Pages
Download PDF

Impressive Response to TANDEM Peptide Receptor Radionuclide Therapy with 177Lu/225AcDOTA-LM3 Somatostatin Receptor Antagonist in a Patient with Therapy-Refractory, Rapidly Progressive Neuroendocrine Neoplasm of the Pancreas

  • Elisabetta Perrone,
  • Kriti Ghai,
  • Aleksandr Eismant,
  • Mikkel Andreassen,
  • Seppo W. Langer,
  • Ulrich Knigge,
  • Andreas Kjaer and
  • Richard P. Baum
Diagnostics2024, 14(9), 907;https://doi.org/10.3390/diagnostics14090907

26 April 2024

The present report describes the history of a 58-year-old woman with a rapidly progressing neuroendocrine pancreatic tumor (initially G2) presenting with extensive liver, bone, and lymph node metastases. Previous treatments included chemotherapy, hem...

Full Article
  • Article
  • Open Access
3 Citations
3,019 Views
16 Pages
Download PDF

Peptide Receptor Radionuclide Therapy (PRRT) Using Actinium-225- and Ac-225/Lutetium-177-Labeled (TANDEM) Somatostatin Receptor Antagonist DOTA-LM3 in Patients with Neuroendocrine Neoplasm: A Retrospective Study Concerning Safety and Survival

  • Elisabetta Perrone,
  • Maria Lucia Calcagni,
  • Lucia Leccisotti,
  • Roberto Moretti,
  • Kriti Ghai,
  • Aleksandr Eismant,
  • Tanay Parkar,
  • Lukas Greifenstein and
  • Richard Paul Baum
Cancers2025, 17(18), 3070;https://doi.org/10.3390/cancers17183070

19 September 2025

Peptide Receptor Radionuclide Therapy (PRRT) offers radiomolecular precision medicine for somatostatin receptor (SSTR)-positive advanced neuroendocrine neoplasms (NEN). In cases resistant to Lutetium-177-labeled DOTATATE or DOTATOC PRRT, alpha-therap...

Full Article
  • Article
  • Open Access
12 Citations
3,235 Views
17 Pages
Download PDF

Early Complications of Radioisotope Therapy with Lutetium-177 and Yttrium-90 in Patients with Neuroendocrine Neoplasms—A Preliminary Study

  • Barbara Bober,
  • Marek Saracyn,
  • Kornelia Zaręba,
  • Arkadiusz Lubas,
  • Paweł Mazurkiewicz,
  • Ewelina Wilińska and
  • Grzegorz Kamiński
J. Clin. Med.2022, 11(4), 919;https://doi.org/10.3390/jcm11040919

10 February 2022

Neuroendocrine neoplasms (NENs) constitute a heterogenous group of tumors originating from neuroendocrine cells scattered throughout the body. Peptide Receptor Radionuclide Therapy (PRRT) is a treatment of choice of unresectable metastasized progress...

Full Article
  • Review
  • Open Access
34 Citations
7,203 Views
32 Pages
Download PDF

Peptide Receptor Radionuclide Therapy Targeting the Somatostatin Receptor: Basic Principles, Clinical Applications and Optimization Strategies

  • Niloefar Ahmadi Bidakhvidi,
  • Karolien Goffin,
  • Jeroen Dekervel,
  • Kristof Baete,
  • Kristiaan Nackaerts,
  • Paul Clement,
  • Eric Van Cutsem,
  • Chris Verslype and
  • Christophe M. Deroose
Cancers2022, 14(1), 129;https://doi.org/10.3390/cancers14010129

28 December 2021

Peptide receptor radionuclide therapy (PRRT) consists of the administration of a tumor-targeting radiopharmaceutical into the circulation of a patient. The radiopharmaceutical will bind to a specific peptide receptor leading to tumor-specific binding...

Full Article
  • Review
  • Open Access
15 Citations
4,200 Views
13 Pages
Download PDF

Renal and Red Marrow Dosimetry in Peptide Receptor Radionuclide Therapy: 20 Years of History and Ahead

  • Stephan Walrand and
  • François Jamar
Int. J. Mol. Sci.2021, 22(15), 8326;https://doi.org/10.3390/ijms22158326

3 August 2021

The development of dosimetry and studies in peptide receptor radionuclide therapy (PRRT) over the past two decades are reviewed. Differences in kidney and bone marrow toxicity reported between 90Y, 177Lu and external beam radiotherapy (EBRT) are disc...

Full Article